Chargement en cours...
Pendant HDAC Inhibitor SAHA Derivatized Polymer as a Novel Prodrug Micellar Carrier for Anticancer Drugs
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDACI) approved by FDA for the treatment of cutaneous T cell lymphoma, is a promising anticancer drug for various cancers with a unique mode of action. However, it demonstrates limited clinical benefits in solid tumors as a sin...
Enregistré dans:
| Publié dans: | J Drug Target |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6107352/ https://ncbi.nlm.nih.gov/pubmed/29251528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/1061186X.2017.1419355 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|